DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy

Assessment of XPD Lys751Gln and XRCC1 T–77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy

“…A large body of evidence from molecular epidemiology has demonstrated that the reduced DRC due to genetic polymorphisms is one of the determinants in genetic susceptibility to cancer [9,19], suggesting these kinds of polymorphisms in DNA repair genes might also be involved in the efficacy of platinum-based chemotherapy in advanced NSCLC. Totally, six DNA repair pathways have been identified to fix the specific types of damaged DNA, including the nucleotide excision (NER) and base excision repair (BER) pathways [20].…”

Clinical impact of ki-67 labeling index in non-small cell lung cancer

“…No statistically significant differences were observed regarding response rates (p = 0.085) or overall survival (p = 0.51) between the 3 groups. Van de Vaart et al [63] included 27 stage III patients who received concommitant cisplatin and radiotherapy (total dose 55 gy). No difference in overall survival was observed between the 3 groups neither in univariate analysis (p = 0.13) nor in multivariate analysis (p = 0.08).…”

Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients

“…These mono-/bifunctional adducts are the major mechanism for the cytotoxicity of the drug. Clinical outcome, measured as either response to chemotherapy or survival, may be better in patients with higher levels of Plt-DNA adducts [7][8][9].…”